Tafasitamab
- Generic Name
- Tafasitamab
- Brand Names
- Monjuvi, Minjuvi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1422527-84-1
- Unique Ingredient Identifier
- QQA9MLH692
- Background
Tafasitamab is a humanized, CD19-directed cytolytic monoclonal antibody intended for the treatment of B-cell malignancies. It is produced using recombinant DNA technology in Chinese hamster ovary cells, and contains an IgG1/2 hybrid Fc-domain which has been modified with 2 amino acid substitutions to enhance its cytotoxicity relative to non-engineered anti-C...
- Indication
Tafasitamab is indicated, in combination with lenalidomide, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified whom are ineligible for autologous stem cell transplant (ASCT).
- Associated Conditions
- Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Relapsed Diffuse large B-cell lymphoma NOS
- Associated Therapies
- -
Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-07-25
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 244
- Registration Number
- NCT06521255
- Locations
- 🇨🇳
Xinjiang Medical University Affiliated Cancer Hospital, Urumqi, China
🇨🇳Henan Cancer Hospital, Zhengzhou, China
🇨🇳Beijing Hospital, Beijing, China
Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 25
- Registration Number
- NCT06465433
- Locations
- 🇹🇷
Gazi University Hospital Gazi University Faculty of Medicine, Ankara, Turkey
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
🇮🇹Hospital S.M. Terni University of Perugia, Terni, Italy
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
- Conditions
- Interventions
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 47
- Registration Number
- NCT06434363
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Alvaro Alencar, MD
- Target Recruit Count
- 27
- Registration Number
- NCT06029309
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- Conditions
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyDrug: LenalidomideProcedure: Lumbar PunctureProcedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyBiological: TafasitamabDrug: Venetoclax
- First Posted Date
- 2023-06-20
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Academic and Community Cancer Research United
- Target Recruit Count
- 100
- Registration Number
- NCT05910801
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- Conditions
- Interventions
- First Posted Date
- 2023-06-06
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 227
- Registration Number
- NCT05890352
- Locations
- 🇺🇸
SWOG, Portland, Oregon, United States
🇺🇸Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States
🇺🇸Saint Joseph Mercy Brighton, Brighton, Michigan, United States
Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE As Salvage Therapy for Transplant Eligible Patients with Relapsed/ Refractory Large B-Cell Lymphoma
- Conditions
- Recurrent B-Cell Lymphoma, Unclassifiable, with Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Grade 3b Follicular LymphomaRecurrent High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 RearrangementsRecurrent High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 RearrangementsRecurrent High Grade B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg TypeRecurrent Primary Mediastinal (Thymic) Large B-Cell LymphomaRecurrent T-Cell/Histiocyte-Rich Large B-Cell LymphomaRecurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2023-04-20
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- David Bond, MD
- Target Recruit Count
- 37
- Registration Number
- NCT05821088
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma
- First Posted Date
- 2023-03-28
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT05788289
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge (All protocol activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (All protocol activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (All protocol activities), Montvale, New Jersey, United States
Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder
- Conditions
- Interventions
- First Posted Date
- 2023-03-27
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Timothy Voorhees
- Target Recruit Count
- 28
- Registration Number
- NCT05786040
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸University of North Carolina-Hillsborough Campus, Hillsborough, North Carolina, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-11-23
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 70
- Registration Number
- NCT05626322
- Locations
- 🇺🇸
LSU Health Baton Rouge North Clinic, Baton Rouge, Louisiana, United States
🇺🇸Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States
🇺🇸Thompson Cancer Survival Center, Knoxville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.